---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-002739"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T21:42:53.874356+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioCryst Q1 ORLADEYO revenue $134.2M (+51% YoY); raises FY guidance to $580-600M; expects FY 2025 profitability

## Summary
- Q1 ORLADEYO net rev $134.2M (+51% YoY); total rev $145.5M (+56.8% YoY); net income $32K vs loss $35.4M.
- FY 2025 ORLADEYO rev guidance raised to $580-600M (from $535-550M); company expects net income and positive cash flow for full year.
- Paid down $75M of Pharmakon debt in April; expects ~$23.5M interest savings over life of loan.
- NDA submitted for ORLADEYO oral granules for HAE children aged 2-11; IND cleared for BCX17725 for Netherton syndrome.
- % paid ORLADEYO patients increased to ~84% (from 73.5% end 2024); U.S. preference for oral prophylaxis rose to 70%.

## SEC filing metadata
- accession: 0001171843-25-002739
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184325002739/0001171843-25-002739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184325002739/f8k_050525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-002739
- JSON: https://secwatch.observer/filing/0001171843-25-002739.json
- Plain text: https://secwatch.observer/filing/0001171843-25-002739.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.